189 related articles for article (PubMed ID: 16648037)
21. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
Akhtar S; Maghfoor I
N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
[No Abstract] [Full Text] [Related]
22. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
Sano T; Sakai H; Takimoto K; Ohno H
Int J Clin Oncol; 2007 Feb; 12(1):59-62. PubMed ID: 17380444
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma.
Coiffier B
Curr Hematol Rep; 2003 Jan; 2(1):23-9. PubMed ID: 12901151
[TBL] [Abstract][Full Text] [Related]
25. Primary diffuse large B-cell lymphoma of the stomach.
Ferreri AJ; Montalbán C
Crit Rev Oncol Hematol; 2007 Jul; 63(1):65-71. PubMed ID: 17339119
[TBL] [Abstract][Full Text] [Related]
26. Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma.
Gibson AD
Clin Lymphoma; 2004 Sep; 5(2):81-3. PubMed ID: 15453921
[No Abstract] [Full Text] [Related]
27. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
28. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
Tobinai K
Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
[TBL] [Abstract][Full Text] [Related]
29. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
[No Abstract] [Full Text] [Related]
30. Optimizing rituximab in B-cell lymphoma.
Horning SJ
J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
[No Abstract] [Full Text] [Related]
31. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
32. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
33. New monoclonal antibody approved as lymphoma therapy.
Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
[No Abstract] [Full Text] [Related]
34. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Mian M; Rass C; Hutarew G; Kofler B; Fiegl M; Greil R
Leuk Lymphoma; 2006 Aug; 47(8):1683-5. PubMed ID: 16966286
[No Abstract] [Full Text] [Related]
35. A malignant fibroleiomyoma of the testis.
Avanzi GC; Castello L; Sainaghi PP; Bergamasco L; Boldorini R; Bartoli E
Clin Lymphoma Myeloma; 2006 Mar; 6(5):414-6. PubMed ID: 16640821
[TBL] [Abstract][Full Text] [Related]
36. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
37. Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.
Brusamolino E; Maffioli M; Bonfichi M; Vitolo U
Future Oncol; 2008 Apr; 4(2):199-210. PubMed ID: 18407733
[TBL] [Abstract][Full Text] [Related]
38. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
[TBL] [Abstract][Full Text] [Related]
39. Factors predicting the response to rituximab in indolent lymphoma.
Lee D
Clin Lymphoma; 2003 Jun; 4(1):19-21. PubMed ID: 12837149
[No Abstract] [Full Text] [Related]
40. NICE announces guidelines for use of rituximab.
Mayor S
BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
